Indaptus Therapeutics (INDP)
Develops systemically administered bacterial immunotherapy for cancer and antiviral applications.
Something off on this page? Send us feedback.
Develops Decoy20, a systemically administered bacterial immunotherapy intended to activate innate and adaptive immune pathways for cancer and antiviral applications. With no approved products or product-sales revenue, operations depend on securities issuance, outsourced development partners, and further regulatory work.
Develops Decoy20, a systemically administered bacterial immunotherapy built from killed, non-pathogenic Gram-negative bacteria with reduced endotoxin activity. The Decoy platform is intended to activate innate and adaptive immune pathways for cancer and antiviral applications; Decoy20 was studied in advanced solid tumors, alone and with tislelizumab.
Operates from New York with a small internal team that uses external manufacturers, CROs, medical institutions, investigators, and laboratories. With no approved products or product-sales revenue, operations are funded primarily through securities issuance. Enrollment in the Decoy20 study ended, no participants remained, and management had no current plan for another trial while evaluating an investment in or acquisition of an operating business. Further development depends on regulatory approval, third-party execution, and external capital.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $11.6M · Total debt $0 · Total assets $12.0M · Shareholders' equity $11.4M
- Revenue
- $0
- Operating income
- −$1.8M
- Net income
- −$1.8M
No dividends on record.
| Institutions6 holders · as of Mar 31, 2026 | 0.05% | 70.6K shares | |
| Insiders9 holders · as of Jun 26, 2026 | 48.75% | 64.95M shares | |
| Strategic holders1 holder · as of Apr 2, 2026 | 29.19% | 38.90M shares | |
| Otherremainder | 22.01% | 29.32M shares |
133.24M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (133.24M in the company's Sep 3, 2026 report, 113.24M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Yun YaoInsider10 percent owner | 31.51% | 41.99M | 13Dfiled Jun 26, 2026 ↗ |
SINO LION VENTURES LtdStrategic10 percent owner | 29.19% | 38.90M | Form 4filed Apr 2, 2026 ↗ |
Junyi DaiInsiderofficer: Chief Executive Officer | 8.44% | 11.25M | 13Dfiled Jun 26, 2026 ↗ |
Yang TingInsider | 8.44% | 11.25M | 13Dfiled Jun 26, 2026 ↗ |
Jeffrey A. MecklerInsiderdirector, 10 percent owner, officer: Co-Chief Executive Officer | 0.17% | 229,929 | Form 4filed Dec 29, 2025 ↗ |
| See all 23 → | |||
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 23, 2026 | David E. Lazar | director | −896,800 |
- Merck
Dominant checkpoint-immunotherapy rival in advanced solid tumors.
- Bristol-Myers Squibb
Broad PD-1 and CTLA-4 portfolio for advanced solid tumors.
- AstraZeneca (ADR)
PD-L1 and CTLA-4 regimens across advanced solid tumors.
- GSK (ADR)
PD-1 treatment for dMMR recurrent or advanced solid tumors.
- Amgen
Oncolytic immune therapy and combination overlap in melanoma.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Indaptus Therapeutics | $1.16 | +1.08% | $132.5M | — | — | — | — |
| Merck | $151.86 | +0.15% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Bristol-Myers Squibb | $67.88 | +0.34% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| AstraZeneca (ADR) | $163.88 | +1.37% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| GSK (ADR) | $50.65 | +0.45% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| Amgen | $442.50 | −0.08% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Median | 24.3 | 15.2 | 4.1 | +5.7% |